Anti-tumor effects of an oncolytic adenovirus expressing hemagglutinin-neuraminidase of newcastle disease virus in vitro and in vivo

Viruses

Volumn 6, Issue 2, 2014, Pages 856-874

  He, Dongyun ^a,b,c   Sun, Lili ^d   Li, Chang ^b,e   Hu, Ningning ^b,e   Sheng, Yuan ^b   Chen, Zhifei ^b   Li, Xiao ^b,e   Chi, Baorong ^a   Jin, Ningyi ^b,e  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c JILIN UNIVERSITY   (China)

^d Tumor Hospital of Jilin Province   (China)

^e Key Laboratory of Jilin Province for Zoonosis Prevention and Control   (China)

Author keywords

Anti tumor; Apoptosis; Esophageal cancer; Hemagglutinin neuraminidase gene; Oncolytic adenoviruses

Indexed keywords

CYTOCHROME C; ONCOLYTIC ADENOVIRUS; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE; GENE EXPRESSION; HEMAGGLUTININ NEURAMINIDASE GENE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR REGRESSION; TUMOR VOLUME; VIRUS RECOMBINANT; WESTERN BLOTTING;

ADENOVIRUSES, HUMAN; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HN PROTEIN; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; TREATMENT OUTCOME;

EID: 84895191030     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v6020856     Document Type: Article

References (36)

1. Marsman, W.A.; Wesseling, J.G.; El Bouch, A.; Bosma, P.J.; van Lanschot, J.J. Adenoviral serotypes in gene therapy for esophageal carcinoma. J. Surg. Res. 2007, 140, 50-54.
2. Hoeben, R.C.; Louz, D.; Koppers-Lalic, D. Biosafety of non-human therapeutic viruses in clinical gene therapy. Curr. Gene Ther. 2013, 13, 492-499.
3. Giacca, M.; Zacchigna, S. Virus-mediated gene delivery for human gene therapy. J. Control. Release 2012, 161, 377-388.
4. Parato, K.A.; Senger, D.; Forsyth, P.A.; Bell, J.C. Recent progress in the battle between oncolytic viruses and tumours. Nat. Rev. Cancer 2005, 5, 965-976.
5. Wong, H.H.; Lemoine, N.R.; Wang, Y. Oncolytic viruses for cancer therapy: Overcoming the Obstacles. Viruses 2010, 2, 78-106.
6. Borel, F.; Kay, M.A.; Mueller, C. Recombinant AAV as a Platform for Translating the Therapeutic Potential of RNA Interference. Mol. Ther. 2013, doi: 10.1038/mt.2013.285.
7. Sinkovics, J.G.; Horvath, J.C. Newcastle disease virus (NDV): Brief history of its oncolytic strains. J. Clin. Virol. 2000, 16, 1-15.
8. Schirrmacher, V.; Griesbach, A.; Ahlert, T. Antitumor effects of Newcastle Disease virus in vivo: Local versus systemic effects. Int. J. Oncol. 2001, 18, 945-952.
9. Ni, J.; Galani, I.E.; Cerwenka, A.; Schirrmacher, V.; Fournier, P. Antitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity. Vaccine 2011, 29, 1185-1193.
10. Iorio, R.M.; Field, G.M.; Sauvron, J.M.; Mirza, A.M.; Deng, R.; Mahon, P.J.; Langedijk, J.P. Structural and functional relationship between the receptor recognition and neuraminidase activities of the Newcastle disease virus hemagglutinin-neuraminidase protein: Receptor recognition is dependent on neuraminidase activity. J. Virol. 2001, 75, 1918-1927.
11. Zeng, J.; Fournier, P.; Schirrmacher, V. High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules. Int. J. Oncol. 2004, 25, 293-302.
12. Scheid, A.; Choppin, P.W. Isolation and purification of the envelope proteins of Newcastle disease virus. J. Virol. 1973, 11, 263-271.
13. Hu, S.; Wang, T.; Liu, Y.; Meng, C.; Wang, X.; Wu, Y.; Liu, X. Identification of a variable epitope on the Newcastle disease virus hemagglutinin-neuraminidase protein. Vet. Microbiol. 2010, 140, 92-97.
14. Zeng, J.; Fournier, P.; Schirrmacher, V. Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 2002, 297, 19-30.
15. Shay, J.W.; Wright, W.E. Telomerase therapeutics for cancer: Challenges and new directions. Nat. Rev. Drug Discov. 2006, 5, 577-584.
16. Harley, C.B. Telomerase and cancer therapeutics. Nat. Rev. Cancer 2008, 8, 167-179.
17. Renvoize, C.; Biola, A.; Pallardy, M.; Breard, J. Apoptosis: Identification of dying cells. Cell Biol. Toxicol. 1998, 14, 111-120.
18. He, X.P.; Su, C.Q.; Wang, X.H.; Pan, X.; Tu, Z.X.; Gong, Y.F.; Gao, J.; Liao, Z.; Jin, J.; Wu, H.Y.; et al. E1B-55 kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer. Cancer Lett. 2009, 285, 89-98.
19. Ji, X.; Zhang, J.; Cheng, L.; Wei, F.; Li, H.; Liu, X.; Chen, X.; Li, C.; Wang, Y.; Huang, Q. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp. Eye Res. 2009, 89, 193-199.
20. Fang, L.; Huang, Y.; Hu, X.; Sun, L.; He, X.; Hu, H.; Pu, Y.; Cao, X.; Luo, H.; Pan, S.; et al. A truncated minimal-E1a gene with potency to support adenoviral replication mediates antitumor activity by down-regulating Neu expression and preserving Rb function. Chem. Biol. Interact. 2009, 181, 1-7.
21. Young, L.S.; Dawson, C.W.; Eliopoulos, A.G. Viruses and apoptosis. Br. Med. Bull. 1997, 53, 509-521.
22. Ravindra, P.V.; Tiwari, A.K.; Ratta, B.; Chaturvedi, U.; Palia, S.K.; Chauhan, R.S. Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosis. Virus Res. 2009, 141, 13-20.
23. Cassel, W.A.; Garrett, R.E. Newcastle Disease Virus as an antineoplastic agent. Cancer 1965, 18, 863-868.
24. Elankumaran, S.; Rockemann, D.; Samal, S.K. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J. Virol. 2006, 80, 7522-7534.
25. Ravindra, P.V.; Tiwari, A.K.; Ratta, B.; Bais, M.V.; Chaturvedi, U.; Palia, S.K.; Sharma, B.; Chauhan, R.S. Time course of Newcastle disease virus-induced apoptotic pathways. Virus Res. 2009, 144, 350-354.
26. Ravindra, P.V.; Tiwari, A.K.; Ratta, B.; Chaturvedi, U.; Palia, S.K.; Subudhi, P.K.; Kumar, R.; Sharma, B.; Rai, A.; Chauhan, R.S. Induction of apoptosis in Vero cells by Newcastle disease virus requires viral replication, de-novo protein synthesis and caspase activation. Virus Res. 2008, 133, 285-290.
27. Meng, S.; Zhou, Z.; Chen, F.; Kong, X.; Liu, H.; Jiang, K.; Liu, W.; Hu, M.; Zhang, X.; Ding, C.; Wu, Y. Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo Cancer Lett. 2012, 317, 56-64.
28. Trowbridge, R.; Sharma, P.; Hunter, W.J.; Agrawal, D.K. Vitamin D receptor expression and neoadjuvant therapy in esophageal adenocarcinoma. Exp. Mol. Pathol. 2012, 93, 147-153.
29. Ye, F.; Zhang, G.H.; Guan, B.X.; Xu, X.C. Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World J. Gastroenterol. 2012, 18, 126-135.
30. Bokemeyer, C.; van Cutsem, E.; Rougier, P.; Ciardiello, F.; Heeger, S.; Schlichting, M.; Celik, I.; Kohne, C.H. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 2012, 48, 1466-1475.
31. Papineni, S.; Chintharlapalli, S.; Abdelrahim, M.; Lee, S.O.; Burghardt, R.; Abudayyeh, A.; Baker, C.; Herrera, L.; Safe, S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 2009, 30, 1193-1201.
32. Li, X.; Liu, Y.; Wen, Z.; Li, C.; Lu, H.; Tian, M.; Jin, K.; Sun, L.; Gao, P.; Yang, E.; et al. Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo Mol. Cancer 2010, 9, doi:10.1186/1476-4598-9-10.
33. Li, X.; Lian, H.; Guan, G.; Sun, L.; Li, X.; Zheng, H. Construction and anti-tumor effects of recombinant fowlpox virus expressing Newcastle disease virus hemagglutinin-neuramidinase gene Chin. Sci. Bull. 2006, 51, 2724-2730.
34. Li, X.; Jin, N.; Mi, Z.; Lian, H.; Sun, L.; Zheng, H. Antitumor effects of a recombinant fowlpox virus expressing Apoptin in vivo and in vitro. Int. J. Cancer 2006, 119, 2948-2957.
35. Image-pro plus, version 5.0.2; Media Cybernetics, Inc: Rockville, MD, USA, 1993-2006.
36. Circu, M.L.; Aw, T.Y., Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med. 2010, 48, 749-762.